Celgene to resubmit ozanimod NDA in 1Q19, updates guidance

Celgene Corp. (NASDAQ:CELG) said in its 1Q18 earnings that it plans to submit regulatory applications to FDA and EMA for relapsing multiple sclerosis candidate ozanimod in 1Q19. The timeline settled uncertainty among analysts

Read the full 330 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE